Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.

Autor:	Wessels AM; Eli Lilly and Company, Indianapolis, Indiana, USA., Lines C; Merck & Co., Inc., Kenilworth, New Jersey, USA., Stern RA; Alzheimer's Disease Center, Boston University School of Medicine, Boston, Massachusetts, USA., Kost J; Merck & Co., Inc., Kenilworth, New Jersey, USA., Voss T; Merck & Co., Inc., Kenilworth, New Jersey, USA., Mozley LH; Merck & Co., Inc., Kenilworth, New Jersey, USA., Furtek C; Merck & Co., Inc., Kenilworth, New Jersey, USA., Mukai Y; Merck & Co., Inc., Kenilworth, New Jersey, USA., Aisen PS; University of Southern California, San Diego, California, USA., Cummings JL; Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV) and Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA., Tariot PN; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Vellas B; Gerontopole, INSERM U1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France., Dupre N; Merck & Co., Inc., Kenilworth, New Jersey, USA., Randolph C; MedAvante-ProPhase, Hamilton, NJ and Department of Neurology, Loyola University Medical Center, Maywood, Illinois, USA., Michelson D; Merck & Co., Inc., Kenilworth, New Jersey, USA., Andersen SW; Eli Lilly and Company, Indianapolis, Indiana, USA., Shering C; AstraZeneca, Boston, Massachusetts, USA., Sims JR; Eli Lilly and Company, Indianapolis, Indiana, USA., Egan MF; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2020 Nov; Vol. 16 (11), pp. 1483-1492. Date of Electronic Publication: 2020 Oct 13.
DOI:	10.1002/alz.12164
Abstrakt:	Introduction: The APECS and AMARANTH trials showed that beta-secretase (BACE) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease. Here, the performance on secondary and exploratory cognitive measures in both studies is reported. Methods: APECS (verubecestat) and AMARANTH (lanabecestat) were randomized, double-blind, placebo-controlled, parallel-group, 104-week clinical trials conducted by different sponsors. Measures included the 3-Domain Composite Cognition Score (CCS-3D), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Letter/Category Fluency, and Digit Symbol Coding. Results: Verubecestat showed worsening on the CCS-3D Total Score, Episodic Memory, and Attention/Processing Speed domains. Lanabecestat showed worsening on the RBANS Total Score, Immediate Memory, and Visuospatial/Constructional Indexes. Both BACE inhibitors showed worsening on Digit Symbol Coding and improvements on Letter/Category Fluency. Discussion: In both studies, many measures showed treatment-associated cognitive worsening, whereas verbal fluency tasks showed improvement. (© 2020 the Alzheimer's Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu